Publication

Pantoprazole in ICU patients at risk for gastrointestinal bleeding-1-year mortality in the SUP-ICU trial

SUP-ICU Trial Investigators, Marker, S., Krag, M., Perner, A., Wetterslev, J., Lange, T., Wise, M. P., Borthwick, M., Bendel, S., Keus, F., Guttormsen, A. B., Schefold, J. C., Rasmussen, B. S., Elkmann, T., Bestle, M., Arenkiel, B., Laake, J. H., Kamper, M. K., Lang, M., Pawlowicz-Dworzanska, M. B., Karlsson, S., Liisanantti, J., Dey, N., Knudsen, H., Granholm, A. & Moller, M. H., Oct-2019, In : Acta Anaesthesiologica Scandinavica. 63, 9, p. 1184-1190 7 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Pantoprazole in ICU patients at risk for gastrointestinal bleeding—1‐year mortality in the SUP‐ICU trial

    Final publisher's version, 620 KB, PDF document

    Request copy

DOI

  • SUP-ICU Trial Investigators
  • Soren Marker
  • Mette Krag
  • Anders Perner
  • Jorn Wetterslev
  • Theis Lange
  • Matt P. Wise
  • Mark Borthwick
  • Stepani Bendel
  • Frederik Keus
  • Anne Berit Guttormsen
  • Joerg C. Schefold
  • Bodil S. Rasmussen
  • Thomas Elkmann
  • Morten Bestle
  • Bjorn Arenkiel
  • Jon H. Laake
  • Maj K. Kamper
  • Maarit Lang
  • Malgorzata B. Pawlowicz-Dworzanska
  • Sari Karlsson
  • Janne Liisanantti
  • Nilanjan Dey
  • Heidi Knudsen
  • Anders Granholm
  • Morten Hylander Moller

Background The long-term effects of stress ulcer prophylaxis with pantoprazole are unknown in ICU patients. We report 1-year mortality outcome in the Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU) trial. Methods In the SUP-ICU trial, acutely admitted adult ICU patients at risk of gastrointestinal bleeding were randomised to intravenous pantoprazole 40 mg vs placebo (saline) once daily during their ICU stay. We assessed mortality at 1 year and did sensitivity analyses according to the trial protocol and statistical analysis plan. Results A total of 3261 of the 3291 patients with available data (99.1%) were followed up at 1 year after randomisation; 1635 were allocated to pantoprazole and 1626 to placebo. At 1 year after randomisation, 610 of 1635 patients (37.3%) had died in the pantoprazole group as compared with 601 of 1626 (37.0%) in the placebo group (relative risk, 1.01; 95% confidence interval 0.92-1.10). The results were consistent in the sensitivity analysis adjusted for baseline risk factors and in those of the per-protocol population. We did not observe heterogeneity in the effect of pantoprazole vs placebo on 1-year mortality in the predefined subgroups, that is, patients with and without shock, mechanical ventilation, liver disease, coagulopathy, high disease severity (SAPS II > 53) or in medical vs surgical ICU patients. Conclusion We did not observe a difference in 1-year mortality among acutely admitted adult ICU patients with risk factors for gastrointestinal bleeding allocated to stress ulcer prophylaxis with pantoprazole or placebo during the ICU stay. (The SUP-ICU trial was funded by Innovation Fund Denmark and others; ClinicalTrials.gov number, NCT02467621).

Original languageEnglish
Pages (from-to)1184-1190
Number of pages7
JournalActa Anaesthesiologica Scandinavica
Volume63
Issue number9
Publication statusPublished - Oct-2019

    Keywords

  • all-cause mortality, gastrointestinal bleeding, intensive care unit, long-term follow-up, stress ulcer prophylaxis, stress ulceration, INTENSIVE-CARE-UNIT, STRESS-ULCER PROPHYLAXIS, SEPSIS, SCORE

View graph of relations

ID: 96181388